Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.: PROVE2: Telaprevir with PEG-IFN and RBV in HCV

Abstract : BACKGROUND: In patients with chronic infection with hepatitis C virus (HCV) genotype 1, treatment with peginterferon alfa and ribavirin for 48 weeks results in rates of sustained virologic response of 40 to 50%. Telaprevir is a specific inhibitor of the HCV serine protease and could be of value in HCV treatment. METHODS: A total of 334 patients who had chronic infection with HCV genotype 1 and had not been treated previously were randomly assigned to receive one of four treatments involving various combinations of telaprevir (1250 mg on day 1, then 750 mg every 8 hours), peginterferon alfa-2a (180 microg weekly), and ribavirin (dose according to body weight). The T12PR24 group (81 patients) received telaprevir, peginterferon alfa-2a, and ribavirin for 12 weeks, followed by peginterferon alfa-2a and ribavirin for 12 more weeks. The T12PR12 group (82 patients) received telaprevir, peginterferon alfa-2a, and ribavirin for 12 weeks. The T12P12 group (78 patients) received telaprevir and peginterferon alfa-2a without ribavirin for 12 weeks. The PR48 (control) group (82 patients) received peginterferon alfa-2a and ribavirin for 48 weeks. The primary end point, a sustained virologic response (an undetectable HCV RNA level 24 weeks after the end of therapy), was compared between the control group and the combined T12P12 and T12PR12 groups. RESULTS: The rate of sustained virologic response for the T12PR12 and T12P12 groups combined was 48% (77 of 160 patients), as compared with 46% (38 of 82) in the PR48 (control) group (P=0.89). The rate was 60% (49 of 82 patients) in the T12PR12 group (P=0.12 for the comparison with the PR48 group), as compared with 36% (28 of 78 patients) in the T12P12 group (P=0.003; P=0.20 for the comparison with the PR48 group). The rate was significantly higher in the T12PR24 group (69% [56 of 81 patients]) than in the PR48 group (P=0.004). The adverse events with increased frequency in the telaprevir-based groups were pruritus, rash, and anemia. CONCLUSIONS: In this phase 2 study of patients infected with HCV genotype 1 who had not been treated previously, one of the three telaprevir groups had a significantly higher rate of sustained virologic response than that with standard therapy. Response rates were lowest with the regimen that did not include ribavirin. (ClinicalTrials.gov number, NCT00372385.)
Type de document :
Article dans une revue
New England Journal of Medicine, Massachusetts Medical Society, 2009, 360 (18), pp.1839-50. 〈10.1056/NEJMoa0807650〉
Liste complète des métadonnées

http://www.hal.inserm.fr/inserm-00385235
Contributeur : Georges Guellaen <>
Soumis le : lundi 18 mai 2009 - 17:03:18
Dernière modification le : vendredi 9 février 2018 - 16:42:04
Document(s) archivé(s) le : jeudi 10 juin 2010 - 23:23:12

Fichier

1839.pdf
Fichiers éditeurs autorisés sur une archive ouverte

Identifiants

Citation

Christophe Hézode, Nicole Forestier, Geoffrey Dusheiko, Peter Ferenci, Stanislas Pol, et al.. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.: PROVE2: Telaprevir with PEG-IFN and RBV in HCV. New England Journal of Medicine, Massachusetts Medical Society, 2009, 360 (18), pp.1839-50. 〈10.1056/NEJMoa0807650〉. 〈inserm-00385235〉

Partager

Métriques

Consultations de la notice

368

Téléchargements de fichiers

779